Company intelligence / Profile preview

Genue

Seoul, South Koreagenuv.com ↗
Ownership
Private
Employees
~50
Development stage
Other
01

Overview

Genuv is a clinical-stage biotechnology company based in South Korea, specializing in the discovery and development of innovative therapeutics for neurodegenerative diseases and immuno-oncology. The company utilizes its proprietary ATRIVIEW platform for phenotypic screening to identify neuroprotective and neuroregenerative drug candidates, and its SHINE MOUSE platform for the discovery of high-affinity monoclonal antibodies. Genuv's lead program, SNR1611 (trametinib), is currently being evaluated in Phase 1/2a clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Additionally, the company is advancing a pipeline of antibody-based therapies, including GNUV201, a novel anti-PD-1 antibody designed for enhanced selectivity in the tumor microenvironment.

Therapeutic areas
NeurologyOncology
Modalities
Small moleculeMonoclonal antibodyBiologicRecombinant fusion proteinPeptides
Industry
Biotech
02

Drug pipeline

1 asset

GNU-101

Unknown

Beyond the preview

Go deeper on Genue.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genue.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call